High-Yield Bonds: Enhanced Valuation and Favorable Short-Term Outlook

Avant Technologies has strengthened the clinical validation for its lead development program, Klothonova, with a new study from the Mayo Clinic demonstrating a strong association between declining alpha-Klotho levels and vascular health. This research reinforces the critical role of alpha-Klotho in vascular health and supports the development of a cell-based therapy to sustainably restore circulating alpha-Klotho levels. The joint venture with Austrianova has secured an exclusive worldwide license from Klothea Bio for the development, manufacture, and commercialization of Klotho-producing cells. Avant's strategic transformation also extends to Insulinova, a joint venture with SGAustria aimed at revolutionizing diabetes treatment through stem cell conversion into insulin-producing cells.